FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.

Fiche publication

Date publication

août 2026

Journal

The Journal of clinical investigation

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DAVIDSON Irwin

Tous les auteurs :
Moreno-Vega A, Zambrano M, Estrada-Virrueta L, Meng X, Puig J, Neyret-Kahn H, Shi M, Dufour F, Gilbert G, Li K, Groeneveld C, Fontugne J, Pérez-Escavy M, Dhifli W, Hua C, Cabel L, Krucker C, Tanguy L, Lindskrog SV, Beraud C, Langle YV, Ye T, Tahi F, Davidson I, Paramio JM, Dyrskjøt L, Allory Y, Lluel P, Eiján AM, Elati M, Radvanyi F, Lodillinsky C, Bernard-Pierrot I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42544574

Résumé

Fibroblast growth factor receptor 3 (FGFR3) is one of the most frequently altered genes in bladder cancer, primarily through activating mutations that drive oncogenesis and are enriched in luminal tumors. However, the underlying gene regulatory network (GRN) remains poorly characterized. Here, we constructed an FGFR3-mutated GRN using a bottom-up bioinformatics approach, integrating transcriptomic data from bladder cancer cell lines, FGFR3-mutated tumors, and FGFR3 perturbation experiments in human and mouse models. Using publicly available CRISPR/Cas9 screening data, we identified transcription factors from this GRN that regulate the viability of FGFR3-mutated cells, with a focus on p63 (TP63). We showed that FGFR3 activation upregulates p63 in patient-derived xenografts and cell lines, while single-cell RNA sequencing revealed heterogeneous p63 activation associated with basal differentiation. Functional studies, including TP63 knockdown in FGFR3-dependent in vitro and in vivo models and RNA-seq along with p63 ChIP-seq, demonstrated that p63 directly promotes cell proliferation and migration and uncovered a positive feedback loop between FGFR3 and p63. Together, these findings support p63 as a protumorigenic regulator in FGFR3-mutated tumors despite their luminal differentiation and provide a detailed FGFR3-driven GRN, offering insights into FGFR3-induced oncogenic dependency and potential strategies to circumvent resistance to FGFR inhibitors.